



Ranexa[®] (ranolazine) – First-time generic

- On February 28, 2019, [Lupin launched](#) an [AB-rated](#) generic version of Gilead's [Ranexa \(ranolazine\)](#) extended-release tablets.
 - Lupin has been granted 180-days of exclusivity.
- Ranexa is approved for the treatment of chronic angina.
- According to IQVIA, Ranexa had sales of approximately \$945 million in the U.S. in 2018.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.